» LEARN ABOUT COVID-19 VARIANTS, VACCINES, TESTING, & VISITOR REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

ECOG-ACRIN - E1A11

Trial

Clinical Trial Title

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Trial Status

Closed to Enrollment

Start Date

February 22, 2017

Trial Type

Cancer - Adult Oncology

Specific Condition

Multiple Myeloma

Description

This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma

Eligibility Criteria

  • Age ≥ 18 years.
  • Must be diagnosed with symptomatic standard-risk multiple myeloma (SR-MM) within 90 days prior to registration.
  • Must have received no more than one cycle (4 weeks or less) of prior chemotherapy and no more than 160mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma.
  • ECOG performance status 0, 1, or 2. (PS 3 allowed if secondary to pain).
  • Must not have active, uncontrolled seizure disorder.
  • Must not have uncontrolled intercurrent illness.
  • Patients with monoclonal gammopathy of undetermined significance or asymptomatic multiple myeloma are not eligible

*Note: HIV infection patients are eligible if meet the following criteria:

  • CD4 cell count ≥ 350/mm3
  • No history of AIDS-related illness
  • Not currently prescribed zidovudine or stavudine

 

IRB Number

Central IRB

Principal Investigator Name

Jacqueline Vuky, MD

Contact Name

Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Contact E-Mail

oncologyresearch@lhs.org

Last Updated: Wednesday, January 27, 2021 12:56:47 PM